Digibug. Repositorio Institucional de la Universidad de Granada
Publication
Artículo científico (JournalArticle)
A 5‑FU Precursor Designed to Evade Anabolic and Catabolic Drug Pathways and Activated by Pd Chemistry In Vitro and In Vivo
We are grateful to the EPSRC (EP/N021134/1) for funding. T.L.B. thanks the CMVM of the University of Edinburgh (Principal's scholarship), and B.R.-R. thanks the EC (H2020MSCA-IF-2014-658833, ChemoBOOM) for financial support. A.U.-B. and D.J.B. thank Medical Research Scotland (PHD-1046-2016) for funding. We acknowledge support from the MRC Confidence in Concept scheme (MRC/CIC6/52) and EPSRC Impact Acceleration Account (PIII024)., 5-Fluorouracil (5-FU) is an antineoplastic antimetabolite
that is widely administered to cancer patients by bolus injection,
especially to those suffering from colorectal and pancreatic cancer.
Because of its suboptimal route of administration and dose-limiting
toxicities, diverse 5-FU prodrugs have been developed to confer oral
bioavailability and increase the safety profile of 5-FU chemotherapy
regimens. Our contribution to this goal is presented herein with the
development of a novel palladium-activated prodrug designed to evade
the metabolic machinery responsible for 5-FU anabolic activation and
catabolic processing. The new prodrug is completely innocuous to cells
and highly resistant to metabolization by primary hepatocytes and liver
S9 fractions (the main metabolic route for 5-FU degradation), whereas
it is rapidly converted into 5-FU in the presence of a palladium (Pd) source. In vivo pharmokinetic analysis shows the prodrug is
rapidly and completely absorbed after oral administration and exhibits a longer half-life than 5-FU. In vivo efficacy studies in a
xenograft colon cancer model served to prove, for the first time, that orally administered prodrugs can be locally converted to active
drugs by intratumorally inserted Pd implants., UK Research & Innovation (UKRI)
Engineering & Physical Sciences Research Council (EPSRC) EP/N021134/1, CMVM of the University of Edinburgh, European Commission
European Commission Joint Research Centre H2020MSCA-IF-2014-658833, Medical Research Scotland PHD-1046-2016, UK Research & Innovation (UKRI)
Medical Research Council UK (MRC) MRC/CIC6/52
UK Research & Innovation (UKRI), Engineering & Physical Sciences Research Council (EPSRC) PIII024